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Abstract
Background: Over the past decade there has been increasing interest in the use of lactic acid bacteria as mucosal delivery
vehicles for vaccine antigens, microbicides and therapeutics. We investigated the mechanism by which a mucosal vaccine
based in recombinant lactic acid bacteria breaks the immunological tolerance of the gut in order to elicit a protective
immune response.
Methodology/Principal Findings: We analyzed how the lipid modification of OspA affects the localization of the antigen in
our delivery vehicle using a number of biochemistry techniques. Furthermore, we examined how OspA-expressing L.
plantarum breaks the oral tolerance of the gut by stimulating human intestinal epithelial cells, peripheral blood
mononuclear cells and monocyte derived dendritic cells and measuring cytokine production. We show that the leader
peptide of OspA targets the protein to the cell envelope of L. plantarum, and it is responsible for protein export across the
membrane. Mutation of the lipidation site in OspA redirects protein localization within the cell envelope. Further, we show
that lipidated-OspA-expressing L. plantarum does not induce secretion of the pro-inflammatory cytokine IL-8 by intestinal
epithelial cells. In addition, it breaks oral tolerance of the gut via Th1/Th2 cell mediated immunity, as shown by the
production of pro- and anti-inflammatory cytokines by human dendritic cells, and by the production of IgG2a and IgG1
antibodies, respectively.
Conclusions/Significance: Lipid modification of OspA expressed in L. plantarum modulates the immune response to this
antigen through a Th1/Th2 immune response.
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Introduction
Over the past decade there has been increasing interest in the
use of lactic acid bacteria (LAB) as mucosal delivery vehicles for
vaccine antigens, microbicides and therapeutics [1]. A number of
studies of oral vaccines generated from genetically engineered
pathogenic or commensal bacteria have been reported [2], [3],
[4], [5], [6], [7], [8], [9], [10], [11]. In humans, Lactobacillus
plantarum belongs to the natural flora of the vagina and the
gastrointestinal tract. We have recently developed an oral vaccine
based in L. plantarum expressing the outer surface protein A
(OspA), a lipoprotein from Borrelia burgdorferi [12].
Evidence suggests that the peptidoglycan layer of some LAB
promote natural immuno-adjuvanticity [13], [14], [15], [16] and
antigen localization on the cell wall makes it more accessible to the
immune system as compared to intracellular or secreted proteins
[17], [18]. Leader peptides mark proteins for translocation across
the cytoplasmic membrane and lipid modification is of major
importance both for anchoring exported proteins to the mem-
brane and for protein function [19]. It has been shown that
lipidation at the first aminoacid of the mature OspA protein is
essential to induce an immune response [20], [21]. In this study,
we examined the influence of post-translational processing in the
localization of OspA lipoprotein on the cell envelope of L.
plantarum.
The normal immune response to harmless gut antigens and
commensal bacteria is the induction of a local and systemic
immunological tolerance, known as oral tolerance [22], [23].
Immunological tolerance can be exploited to develop immuno-
therapies for autoimmune and inflammatory diseases but it is also
the obstacle to the development of oral vaccines [23]. As a result of
our observation that an oral vaccine based in L. plantarum
expressing the OspA lipoprotein induced a protective, IgG-based,
immune response in mice [12] we set out to further understand the
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administration of antigen. We investigated the role of L. plantarum
expressing OspA lipoprotein in breaking the oral tolerance of the
gut and if this immune response was dependent on the lipid
modification of OspA.
Materials and Methods
Ethics statement
The procedures involving human blood were approved by the
Institutional Review Board (IRB) of the University of Tennessee
Health Science Center, under the provisions of the Department of
Health and Human Services Regulations for Protection of Human
Subjects (45 CFR 46) and similar FDA Regulations (21 CFR 50
and 56). All participants provided written informed consent. The
procedures involving mice were in accordance with the Animal
Welfare Act and the Public Health Service Policy on Humane
Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Tennessee Health Science Center.
Bacterial strains, cell lines and culture conditions
L. plantarum was grown at 30uC in LM medium [1% proteose
peptone (w/v), 1% beef extract (w/v), 0.5% yeast extract (w/v),
0.5% lactose (w/v), 9 mM ammonium citrate, 61 mM sodium
acetate anhydrous, 0.4 mM magnesium sulfate, 0.3 mM manga-
nese sulfate, 11.2 mM dipotassium phosphate, 0.5% Tween 20 (v/
v)], supplemented with 10 mg/ml of chloramphenicol (Cm). E. coli
was grown at 37uC in TBY medium (BD, Franklin Lakes, NJ). T84
human colonic carcinoma epithelial cells were obtained from the
American Type Culture Collection (ATCC, CCL-248, Manassas,
VA). T84 cells were maintained at 37uC, 5% CO2 in DMEM-
F12K medium modified by ATCC, containing 10% FCS, 100 U/
ml penicillin and 100 mg/ml streptomycin.
Plasmid construction and characterization of expressed
antigens
A vector that expresses the full-length ospA gene from B.
burgdogferi in L. plantarum was previously described [12]. To
generate a vector expressing the OspA mutant, we designed
primers in which we replaced the codon corresponding to Cys
17
with Asp
17. Expression vectors were then transformed into L.
plantarum strain 256 to obtain the clones LpA and LpAD17,
respectively. Protein expression was checked by immunoblot as
follows. Recombinant L. plantarum cells were disrupted with a
FrenchH press (Thermo Electron Corporation, Milford, MA),
supernatants were analyzed on a 12% denaturing polyacrilamide
gels and electrotransferred to a polyvinylidene difluoride mem-
brane (PVDF, Millipore, Billerica, MA) for analysis with an OspA-
specific monoclonal antibody (mAb 184.1). To evaluate export
and lipidation of OspA and its mutant expressed by recombinant
Lactobacillus, we performed Triton X-114 phase partitioning [24].
L. plantarum cultures were grown overnight at 30uC, harvested and
resuspended to an OD600 of 1.0 in PBS. Bacteria were disrupted
with a FrenchH press and the insoluble material (membrane and
cell wall) was separated from the cytosol fraction by centrifugation.
This cell envelope fraction was suspended in 1 ml of ice-cold 2%
Triton-X114 (v/v) in PBS. The fractions were rotated end over
end at 4uC for 1 h and were phase-separated by warming the
solution for 30 min in a water bath at 37uC followed by
centrifugation for 15 min at 25uC. The separated detergent and
aqueous phases were each washed three times. The solutions were
then rewarmed and recentrifuged as described and the detergent
and aqueous phases were collected. Ten (10) ml of each phase was
analyzed on 15% denaturing polyacrylamide gels, electrotrans-
ferred to PVDF filters, and used for immunoblot analysis. OspA-
specific monoclonal antibody LA2.2 (1:100) was used as primary
antibody, goat anti-mouse IgG (H+L) conjugated to alkaline
phosphatase (1:1000; Pierce Rockford, IL) was used as secondary
antibody and the immunoblot was developed by BCIP/NBT
TM
(KPL, Washington, DC). The protein bands corresponding to
each OspA antigen were quantified by densitometry using a Multi
Image
TM Light Cabinet and the AlphaEase
TM software (Alpha
Innotech Corporation, San Leandro, CA). The results were
plotted as a percentage of the total OspA content for each
recombinant Lactobacillus.
A vectorthatexpressesthefull-lengthospAgenefromB.burgdogferi
in Escherichia coli (EcA) was previously described [25]. To generate
the vector pET9c-mutOspA that expresses the OspA mutant
(mutOspA), we designed primers to amplify the B. burgdorferi ospA
gene lacking the signal sequence and we cloned the PCR fragment
into pET9c. The expression vectors were transformed into E. coli
BL21 (DE3) pLysS, the recombinant proteins were purified and the
endotoxines were removed using the Detoxi-Gel
TM Endotoxin
Removing Gel (Pierce Biotechnology, Rockford, IL).
Cell fractionation assay
Lactobacillus cultures were grown overnight at 30uC, harvested
and resuspended to an OD600 of 1.0 in TGE buffer [25 mM Tris-
HCl pH 8, 50 mM glucose, 10 mM EDTA pH 8]. For cell wall
removal, aliquots of 1 ml were treated with 250 KU/ml of
lysozyme (Lyz; Novagen, Gibbstown, NJ) for 45 min at 37uC.
Protoplasts and cell wall fractions were separated by centrifugation
and the supernatants containing the cell walls collected. Proto-
plasts were washed, resuspended in TED buffer [25 mM Tris-HCl
pH 8, 1 mM EDTA, 1 mM DTT] and disrupted with a FrenchH
press. Supernatants were ultracentrifugated for 1 h to separate
membranes from cytosol fractions. Three (3) mg of each fraction
was analyzed on 15% denaturing polyacrylamide gels, electro-
transferred to PVDF filters and used for immunoblot analysis with
mAb LA2.2 as described above.
Indirect immunofluorescence microscopy
Recombinant Lactobacillus were treated with and without
250 kU/ml of Lyz in TGF buffer [100 mM Tris-HCl pH.8,
50 mM glucose, 1% FBS (v/v) (Hyclone, South Logan, UT)] for
30 min. Cells were washed and resuspended in TGF buffer with
mAb LA2.2 (1:100) for 1 h at room temperature, washed three
times with 500 ml TGF buffer and resuspended on 100 ml of the
same buffer. Aliquots of 10 ml were placed on slides and air-dried
at 37uC for 1 h. Slides were incubated with Alexa Fluor 488-
labeled goat anti-mouse IgG antibody (1:250) (Molecular Probes,
Invitrogen, Carlsbad, CA) in 100 ml TGF buffer at 23uC for 1 h
with intermittent gentle mixing. After incubation, slides were
washed three times with TGF buffer and fixed with 4% PBS–
buffered formaldehyde (methanol free; Ted Pella Inc., Redding,
CA) for an additional 15 min at room temperature. Labeled cells
were mounted in VectaShield medium containing 4,6-diamidino-
2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA) and
visualized using a Zeiss inverted Axiovert 200 motorized
microscope and analyzed using the Axiovision 4.3 software.
Live-cell ELISA (lcELISA)
To further investigate the localization of antigens on the
Lactobacillus cell envelope, we developed an indirect live-cell
enzyme-linked immunosorbent assay (lcELISA). Lactobacillus cul-
tures were grown overnight at 30uC, harvested and resuspended to
an OD600 of 1.0 in TG buffer [100 mM Tris-HCl pH.8, 50 mM
Immunity to rLactobacillus
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11199glucose]. For cell wall digestion, 1 ml aliquots were resuspended in
TG buffer with or without Lyz (250 kU/ml) for 5 or 45 min at
37uC. Cells were washed twice with TG buffer, resuspended in the
same buffer supplemented with 3% BSA (Bovine Serum Albumin,
Sigma), and incubated with mAb LA2.2 (1:500). Samples were
washed twice and incubated for 30 min with goat anti-mouse IgG
(H+L) antibodies conjugated to alkaline phosphatase (1:1000).
After an extensive wash, labeled cells were incubated with pNPP
Microwell Substrate System (KPL). Microtiter plates were loaded
with 100 ml of each cellular suspension, and optical densities were
measured at 405 nm by a Spectra MAX plus ELISA reader
(Molecular Devices, Sunnyvale, CA).
IL-8 production by human epithelial cells
T84 cells (human colon carcinoma epithelial cell line) were
seeded in 24-well tissue culture plates (BD Biosciences, San Jose,
CA) at a density of 1610
6 cells/well and grown until they reached
90 to 95% confluence. L. plantarum cells were killed by exposure to
UV light for 1 h and the lack of cell viability was confirmed by
culture in MRS agar. T84 cells were co-cultured with UV-killed
recombinant L. plantarum at a MOI 10:1 bacteria per cell, for 48 h.
L. plantarum control and 0.5 mg/ml TNFa were used as negative
and positive controls, respectively. Supernatants were collected
and the human IL-8 production was measured by ELISA
(Quantikine, R&D Systems, Minneapolis, MN).
Isolation of human Peripheral Blood Mononuclear Cells
and monocytes
Human peripheral blood was collected into heparin vacutainer
tubes (BD Bioscience, Franklin Lakes, NJ) from healthy individ-
uals. Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll-Paque density gradient centrifugation (GE Healthcare,
Uppsala, Sweden). A final suspension was made in complete
RPMI 1640 (Hyclone), supplemented with 10% [v/v] FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml and
fungizone. Cell viability (greater than 95%) was determined by
trypan blue exclusion. Human monocytes were purified from
PBMC using the Monocyte Isolation Kit II (Miltenyi Biotec,
Auburn, CA), according to the manufacturer’s recommendations.
These monocytes were then used to produce Monocyte Derived
Dendric Cells (MDDC) as described below.
Stimulation for cytokine production
To derive dendritic cells from PBMCs and monocytes we
cultured 1610
6 or 2610
5 cells/well, respectively, in 24-well tissue
culture plates for 5 days in 2 ml of complete RPMI 1640
supplemented with 10 ng/ml IL-4, and 100 ng/ml recombinant
human granulocyte-macrophage colony-stimulating factor (GM-
CSF) (R&D system, Minneapolis, MN). Cultures were placed at
37uC in a 5% CO2 humidified incubator. Every two days the
medium was removed and 2 ml of fresh complete medium was
added. At day 5 the cells were co-cultured with 2.5 mg/ml of
purified recombinant OspA or UV-killed recombinant Lactobacillus
at MOI 10:1 colony-forming units per cell for 48 h at 37uC.
100 ng/ml of lipopolysaccharide (LPS) from Escherichia coli
O111:B4 (LIST Biological Laboratories, Campbell, CA) and L.
plantarum were used as positive and negative control, respectively.
Supernatants were collected and TNFa, IL-12, IFNc, IL-6, and
IL-10 were quantified by ELISA (Quantikine, R&D Systems).
Intragastric inoculation of recombinant L. plantarum
L. plantarum expressing the target antigen was cultured in LM
medium supplemented with 10 mg/ml Cm, and grown at 30uCt o
an OD600 of 1.0. That is the equivalent of 1610
9 cells/ml
corresponding to approximately 125 mg of total protein. The cells
were harvested by centrifugation at 3000 g for 10 min at 4uC and
resuspended in 20% glycerol/phosphate buffered salt solution
(Gibco, Grand Island, NY) in 1% of the initial volume. Cell
suspensions in aliquots of 2 ml were frozen quickly in a dry ice
bath and stored at 280uC. Aliquots were thawed at 4uC and
400 ml( 4 610
10 cells) were placed in a ball-tipped syringe for oral
gavage inoculation. Groups of four female C3H-HeJ mice (6–8
weeks old, Charles River, Boston, MA) were immunized by
intragastric inoculation of 4610
10 Lactobacillus expressing OspA
recombinant antigens. L. plantarum (Lp) was used as control. Mice
received the first immunization, twice daily, for 8 days (days 1–4
and 8–11). After resting for two weeks the mice were bled (day 28).
On days 29–32 they received the 1
st oral boost and rested for an
additional 2 weeks. On day 49, the mice were bled. On days 50–
53 they received the 2
nd oral boost and rested for an additional 2
weeks. On day 68 mice were terminated, and blood, stool and
bronchoalveolar lavage fluids (BAL) were collected. The animals
were housed in a pathogen free colony on hardwood chip bedding
in microisolator cages at the University of Tennessee Health
Science Center, Memphis, TN. They were maintained on a 12 h
light-dark cycle, in a room kept al 23uC with 50–60% relative
humidity; they were given tap water and sterile irradiated rodent
chow ad libitum.
Humoral immune response
Serum, stool and BAL from orally inoculated mice were tested
by indirect ELISA for the presence of total IgG, IgG1, IgG2a or
IgA to OspA. Purified recombinant OspA was coated at 0.5 mg/
ml on Nunc MaxiSorp
TM flat-bottom ELISA plates (eBioscience,
San Diego, CA) and indirect ELISA was performed using serum
(1:500), stool (1:10) or bronchoalveolar fluid. Anti-mouse IgG,
anti-mouse IgG1, anti-mouse IgG2a or anti-mouse IgA horserad-
ish peroxidase-conjugated antibodies (1:2,000) (Jackson Immu-
noResearch, West Grove, PA) was used as secondary antibody.
Statistical Analysis
All data is represented as mean 6 standard deviation. Statistical
analyses were performed using Student’s t-test. p,0.05 are
considered statistically significant.
Results
Construction of recombinant L. plantarum and evaluation
of protein lipidation
Previously, we reported the cloning and expression of full length
OspA from B. burgdorferi in a lactobacilli expression vector and
designed an oral vaccine candidate for Lyme disease (LpA) [12].
For this study, we mutated the conserved lipidation motif of ospA
by replacing the cystein at position 17 with aspartic acid to
generate a protein that lacks the post-translational lipid attach-
ment (Fig.1A). Total extracts of L. plantarum carrying the empty
vector (Lp), and expressing OspA (LpA) or OspAD17 (LpAD17)
were analyzed by SDS-PAGE and protein expression was
confirmed using anti-OspA monoclonal antibody, mAb 184.1
(Fig.1B). The two bands seen for LpA may represent the lipidated
unprocessed OspA protein (the leader peptide has not been
cleaved, 31 kDa) and the lipidated mature protein (the leader
peptide has been cleaved, 30 kDa). The single band seen for
LpAD17 (30.4 kDa) may represent the unlipidated OspA (contain-
ing the leader peptide).
We further evaluated the export and lipidation of OspA and its
mutant by Triton X-114 phase partitioning of the cell envelope
Immunity to rLactobacillus
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detergent phase, suggesting that OspA is exported through the
membrane and that the amount of OspA that is hydrophobic
(,50%) is higher than the hydrophilic form (,40%), although not
significantly so. In contrast, the mutant OspAD17 partitions mostly
to the aqueous phase, suggesting that, in addition to being
exported, the mutant generated more hydrophilic OspA (,70%)
than hydrophobic (,25%) (Fig. 2A and 2B). If about 25% of
OspA is associated with the cell envelope due to hydrophobicity of
the leader sequence (i. e. OspAD17 in the detergent phase of
LpAD17), then the difference (i. e. ,30% additional wildtype OspA
in the detergent phase of LpA) should be protein that is associated
with the cell envelope via the lipid anchor, or the lipidated form of
OspA. Differences for the mutant OspAD17 partitions are
statistically significant (Fig. 2B, *p,0.05).
Localization of recombinant antigens in L. plantarum
Next, we performed serial fractionation experiments in order to
determine where the recombinant proteins are localized within
the cell envelope of L. plantarum (Fig. 3A). We treated recombinant
L. plantarum with Lysozyme (Lyz) for 45 min and separated the cell
wall fraction from the protoplast by centrifugation. We then
disrupted the cells and separated the membrane from the cytosol
fractions by ultracentifugation. The three fractions were then
analyzed on denaturing polyacrylamide gels and OspA was
identified by Immunoblot with anti-OspA monoclonal antibody
(mAb LA2.2). Lipidated OspA expressed in L. plantarum is
exported through the membrane and accumulates in the cell
wall, while unlipidated OspAD17 remains mostly attached to the
membrane (Fig. 3A). Next, we wanted to analyze the localization
of the recombinant proteins on the surface of L. plantarum. We
incubated live recombinant L. plantarum with and without Lyz and
we performed both live-cell ELISA (lcELISA) and immunofluo-
rescence (IFA) assays. For lcELISA, we incubated the recombi-
nant L. plantarum with Lyz for 5 and 45 min, the cells were washed
and incubated with mAb LA2.2 (Fig. 3B). For immunofluores-
cence, we performed a 30 min incubation with Lyz after which
the cells were washed, incubated with mAb LA2.2 followed by
Fluor 488-labeled goat anti-mouse IgG (1:250). Staining was
visualized using a Zeiss inverted Axiovert 200 microscope
(Fig. 3C). In both assays, IFA and lcELISA, reactions without
lyz (No Lyz) detect protein that is exposed on the surface of the
cell. The epitope used to detect OspA and OspAD17 is located in
the carboxyl terminal of the protein and is not surface exposed
(Fig. 3B and 3C). Reactions with Lyz digest the peptidoglycan that
releases the OspA that is trapped within the cell wall and expose
OspA that is attached to the membrane (Lyz 5 min, 45 min or
30 min, Fig. 3B and 3C). Our results indicate that lipidated OspA
(LpA) is trapped within the cell wall. That is, a 5 min digestion
with Lyz exposes a high amount of OspA that is associated with
the peptidoglycan layer (Fig. 3B) and a 45 min or 30 min
digestion exposes a lower amount of OspA that is associated with
the peptidoglycan layer (Fig. 3B and 3C), suggesting that OspA
might not be attached to the membrane. In contrast, unlipidated
OspAD17 (LpAD17) is trapped within the peptidoglycan layer of
the cell wall, maybe attached to the membrane. That is, a 5 min
digestion with Lyz exposes a low amount of OspA that is
associated with the peptidoglycan layer (Fig. 3B) and a 45 min
or 30 min digestion exposes a high amount of OspA that is
associated with the peptidoglycan layer and the membrane
(Fig. 3B and 3C).
Figure 1. Characterization of recombinant Lactobacillus. Sche-
matic representation of the ospA and ospAD17 constructs (A), and
immunoblot characterization (B). Whole-cell extract of control, OspA-
and OspAD17-expressing L. plantarum (Lp, LpA, and LpAD17, respective-
ly) were analyzed on a 12% SDS-PAGE, transferred to PVDF membrane
and tested with OspA-specific monoclonal antibody 184.1. Legend:
pXyl, xylose promoter; MCS, multicloning site; Tcbh, Rho independent
transcriptional terminator.
doi:10.1371/journal.pone.0011199.g001
Figure 2. Evaluation of protein export and lipidation. OspA- and
OspAD17-expressing L. plantarum were disrupted with a FrenchH press,
the insoluble material (cell envelope) was extracted with Triton X-114
and partitioned into detergent and aqueous phases. Protein fractions
were analyzed on a SDS-PAGE and tested by immunoblot with OspA-
specific monoclonal antibody LA2.2 (A). Protein was quantified by
densitometry. The results were plotted as a percentage of the total
OspA content for each recombinant Lactobacillus (B). TE, total extract; D,
detergent phase; A, aqueous phase; OspA- and OspAD17-expressing L.
plantarum (LpA and LpAD17, respectively). *p,0.05.
doi:10.1371/journal.pone.0011199.g002
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In order to analyze the potential inflammatory response to the
oral administration of L. plantarum expressing OspA lipoprotein, we
performed an assay using monolayer cultures of intestinal
epithelial cells (T84), a human colon carcinoma cell line,
stimulated with UV-killed LpA and LpAD17 and determined the
production of IL-8 (Fig. 4). The co-culture of T84 cells with UV-
killed LpA or LpAD17 did not induce significant production of the
pro-inflammatory chemokine IL-8 in comparison to the positive
control (TNFa).
Dendritic cells (DCs) play a decisive role in the innate and
adaptive immune response, as they produce cytokines in response
to antigen stimulation and activated T cells. Monocytes were
isolated from human Peripheral Blood Mononuclear Cells
(PBMCs) and were treated with GM-CSF and IL-4 to derive to
MDDCs. Because OspA is known to trigger TLR2-based
receptors we stimulated MDDCs with purified proteins in order
to access the effect of the naked protein (wildtype OspA (wtOspA)
versus a OspA mutant lacking the leader peptide (mutOspA)), on
cytokine induction. We co-cultured MDDCs with 2.5 mg/ml of
purified wtOspA or mutOspA during 48 h and the production of
pro-inflammatory cytokines TNFa, IL-12, IFNc, and anti-
inflammatory cytokine IL-10 was quantified by ELISA (Fig. 5A,
5B, 5C and 5D, respectively). wtOspA induced TNFa and IL-10
production (Fig 5A and 5D) but it did not induce neither IL-12 nor
IFNc (Fig. 5B and 5C). Compared to wtOspA, the OspA mutant
lacking the leader peptide, mutOspA, showed a 10 fold-decrease in
the TNFa production (Fig. 5A) and a 2 fold-decrease in the IL-10
production (Fig. 5D). Similarly to wtOspA, mutOspA did not induce
neither IL-12 nor IFNc cytokine production (Fig. 5B and 5C).
Differences between wtOspA and mutOspA are statistically
significant (*p,0.001 and **p,0.05).
Next, we treated PBMCs with GM-CSF and IL-4 to derive
the monocyte population into immature dentritic cells (PBMC/
DCs), and we investigated the cytokine production of human
PBMC/DCs co-cultured with UV-killed recombinant L. plan-
tarum expressing either lipidated OspA (LpA), the mutant
unlipidated OspA (LpAD17)o rt h ec o n t r o l( L p ) .T h ea m o u n t
of pro-inflammatory cytokines TNFa,I L - 1 2 ,I F N c and IL-6,
and anti-inflammatory cytokine IL-10 was quantified by ELISA
(Fig. 6). As compared to the control, LpA induced TNFa by 9
fold, IL-12 by 3 fold, IFNc by 4 fold and IL-6 by 10 fold
(Fig. 6A, 6B, 6C and 6D). Additionally, anti-inflammatory
cytokine IL-10 was 7 fold upregulated by stimulation with
recombinant L. plantarum expressing lipidated (LpA) as com-
pared to the control (Lp) (Fig. 6E). Compared to LpA, the
mutant L. plantarum expressing the unlipidated OspA (LpAD17)
induced significantly less TNFa, IL-12, IFNc,I L - 6a n dI L - 1 0
(Fig. 6A, 6B, 6C, 6D and 6E). Differences between LpA and
LpAD17 are statistically significant (*p,0.001 and **p,0.02).
Further, compared to the control (Lp), LpAD17 induced TNFa,
IL-6 and IL-10 (p,0.001). LPS was used as a positive control
and upregulated secretion of all cytokines tested (data not
shown).
Figure 3. Localization of recombinant antigens in L. plantarum. Localization of the recombinant antigens was studied by (A) serial cell
fractionation, (B) live-cell ELISA (lcELISA) and (C) Immunofluorescence Assay (IFA). (A) Immunoblot of cellular fractions of L. plantarum expressing
OspA antigens: C, cytosol; M, membrane; CW, cell wall. L. plantarum was treated with 250 kU/ml Lysozyme (Lyz) for 45 min to digest the cell wall;
protoplasts were disrupted and, membrane and cell wall fractions were separated by ultracentrifugation. 3 mg of each fraction was analyzed in a 12%
SDS-PAGE, transferred to PVDF membrane, and tested by immunoblot with OspA-specific monoclonal antibody LA2.2 (mAb LA2.2). (B) Live
recombinant L. plantarum were treated during 0, 5 or 45 min with Lyz and then subjected to lcELISA using mAb LA2.2 and anti-mouse IgG secondary
antibody labeled with alkaline phosphatase. The Optical Density at 405 nm (OD405) of the mean endpoint titer was determined. The average of
triplicate samples per sample was determined and the error bar indicates standard deviation. (C) Live recombinant L. plantarum were treated with or
without Lyz for 30 min. After cell wall removal, the cells were incubated with mAb LA2.2 followed by Alexa Fluor 488-labeled goat anti-mouse IgG
(1:250) antibodies. Immunofluorescence staining was visualized using a Zeiss inverted Axiovert 200 microscope, and the images were acquired using
AxioVision software. *p,0.001. Results are representative of one of three independent experiments.
doi:10.1371/journal.pone.0011199.g003
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by MACS to derive MDDC and analyzed cytokine production
after stimulation (Fig. 7). As expected, we determined that LpA
induced higher production of proinflammatory cytokines TNFa
(17 fold upregulated), IL-12 (,4 fold upregulated) and IL-6 (1–2
fold upregulated) as compared to the control (Lp) (Fig. 7A, 7B and
7D, respectively). There was no production of IFNc by monocyte
derived dendritic cells (Fig. 7C). Compared to LpA, the mutant L.
plantarum expressing the unlipidated OspA (LpAD17) abrogated this
response as seen by the decreased production of TNFa, IL-12 and
IL-6 (Fig. 7A, 7B and 7D). Additionally, IL-10 was ,2–3 fold
upregulated after stimulation with recombinant L. plantarum
expressing lipidated (LpA) and the mutant appeared to impair
this response (Fig. 7E). Differences between LpA and LpAD17 are
statistically significant (*p,0.05 and **p,0.001).
Antibody response to oral administration of recombinant
L. plantarum
Lastly, to assess the systemic and mucosal antibody immune
response induced by the oral administration of recombinant L.
plantarum, we immunized mice and tested serum levels of OspA-
specific total IgG, IgG1 and IgG2a antibodies (Fig. 8), and the
levels of mucosal OspA-specifc IgA in bronchoalveolar lavage
(BAL) and stool suspensions (Stool) (Fig. 9), by indirect ELISA. In
contrast to the controls, mice orally administered with L. plantarum
expressing lipidated OspA (LpA) or the unlipidated mutant
developed high titers of IgG specific antibody 68 days after the
first inoculation (Fig. 8A). However, mice inoculated with LpA
produced higher levels of OspA-specific IgG1 compared to mice
inoculated with LpAD17, as shown on day 68 after the first
inoculation (**p,0.01) (Fig. 8B). In contrast, mice inoculated with
either LpA or LpAD17 developed equivalent levels of IgG2a
(Fig. 8C). Furthermore, the same mice inoculated with LpA and
LpAD17 developed a high OspA-specific IgA antibody titer in BAL
(Fig. 9A) and stool (Fig. 9B), 68 days after the first inoculation.
Differences between LpA and LpAD17 were not statistically
significant.
Discussion
It is now generally accepted that mucosal vaccines that can elicit
both secretory IgA and effective systemic immune responses could
have advantages over many existing vaccines [1]. A large body of
research has accumulated recently, whereby mucosal vaccines
have been developed using LAB against a vast number of
pathogens to various degrees of efficacy success [26], [27], [28],
[29], [9], [30], [31], [32], [33], [11], [34]. We have recently found
that L. plantarum expressing B. burgdorferi OspA lipoprotein induced
Figure 4. Production of IL-8 in human epithelial cells co-
cultured with recombinant L. plantarum. Human epithelial cells
(T84) were seeded in 24-well plates (10
6 cells/well) and grown until they
reached about 95% confluence. UV-killed L. plantarum expressing OspA
(LpA) or the mutant OspAD17 (LpAD17) were co-cultured with T84 cells at
MOI 10:1 colony-forming units per cell for 48 h and culture
supernatants were collected to determine IL-8 secretion by sandwich
ELISA (Quantikine). 0.5 mg/ml TNFa and UV-killed L. plantarum (Lp) were
used as positive and negative control, respectively. The average of
triplicate samples was determined and the error bar indicates standard
deviation. Results are representative of one of three independent
experiments.
doi:10.1371/journal.pone.0011199.g004
Figure 5. Production of cytokines in human MDDCs co-cultured with purified recombinant wtOspA or mutOspA. Monocytes were
isolated from human PBMCs by MACS using the Monocyte Isolation Kit II. Monocytes were derived to immature DCs (MDDCs) by cultivating the cells
in the presence of 100 nM GM-CSF and 10 nM IL-4 for 5 days. MDDCs (2610
5 cells/well) were seed in 24 well plates and co-cultured with 2.5 mg/ml of
wtOspA or mutOspA. After 48 h of stimulation, supernatants were collected and TNFa (A), IL-12 (B), IFNc (C) and IL-10 (D) cytokine production was
measured by sandwich ELISA (Quantikine). *p,0.001,**p,0.05. Results are representative of one of three independent experiments.
doi:10.1371/journal.pone.0011199.g005
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of oral administration [12]. In the present study, we investigated
the effect of the lipid modification of OspA in the localization of
the antigen in our mucosal delivery vehicle, L. plantarum.
Furthermore, we investigated how recombinant L. plantarum
expressing OspA lipoprotein breaks the oral tolerance of the gut.
We show that the leader peptide of OspA targets the protein to the
cell envelope of the delivery vehicle L. plantarum, and that the Cys
17
is the substract for OspA lipidation. Further, we show that our
recombinant L. plantarum based mucosal delivery system does not
induce secretion of IL-8 by intestinal epithelial cells and that it
breaks oral tolerance of the gut via Th1/Th2 cell mediated
immunity.
Expression of the full-length B. burgdorferi OspA gene in E. coli,a
Gram-negative bacteria, produces a protein that is processed post-
translationally by signal peptidase II and contains an attached lipid
moiety. In E. coli this lipoprotein partitions mostly into the
detergent phase following extraction with Triton X-114 [35]. As
seen in E. coli, we show that in Gram-positive L. plantarum, the
leader peptide also marks OspA for translocation or export across
the cytoplasmic membrane given that wildtype OspA partitions to
the detergent phase following extraction with Triton X-114,
suggesting that it is lipidated. In contrast, the mutant OspAD17,
which lacks the cystein that is needed for the lipid moiety
attachment, partitions mostly to the aqueous phase. This shift on
the solubility of the mutant OspAD17 appears to be due to the lack
of the lipid attachment, that makes the antigen more hydrophilic
than the native lipidated OspA, and therefore the mutant appears
to be unlipidated. It appears that OspA is indeed lipidated and
localizes mostly at the membrane-cell wall interface. This
observation is consistent with a previous study of Gram-positive
Lactococcus spp. lipoprotein processing that found that lipid
modification is predominantly required to retain proteins at the
membrane cell-wall interface [36].
The intestinal immune system is the largest and the most
complex part of the immune system [23]. Crosstalk occurs
between the luminal microorganisms and the mucosal tissue, with
intestinal epithelial cells (IECs) mediating this dialogue. Microbial
Figure 6. Production of cytokines in human PBMC/DCs co-cultured with recombinant Lactobacillus. Human Peripheral Blood
Mononuclear Cells (PBMCs) were treated with 100 nM GM-CSF and 10 nM IL-4 during 5 days to derive monocytes into dendritic cells. 10
6 cells/well
were seed in 24 well plates and co-cultured with UV-killed recombinant Lactobacillus expressing OspA (LpA) or the mutant OspAD17 (LpAD17) at MOI
10:1 colony-forming units per cell. 100 ng/ml Escherichia coli O111:B4 lipopolysaccharide (LPS) and L. plantarum (Lp) were used as positive and
negative control, respectively. After 48 h of stimulation, supernatants were collected and TNFa (A), IL-12 (B), IFNc (C), IL-6 (D) and IL-10 (E) cytokine
production was measured by sandwich ELISA (Quantikine). *p,0.001,**p,0.02. Results are representative of one of three independent experiments.
doi:10.1371/journal.pone.0011199.g006
Figure 7. Production of cytokines in human MDDC co-cultured with recombinant Lactobacillus. Monocytes were isolated from human
PBMCs by MACS using the Monocyte Isolation Kit II. Monocytes were derived to immature DCs (MDDCs) by cultivating the cells in the presence of
100 nM GM-CSF and 10 nM IL-4 for 5 days. MDDCs (2610
5 cells/well) were co-cultured with UV-killed recombinant Lactobacillus expressing OspA
(LpA) or the mutant OspAD17 (LpAD17) at MOI 10:1 colony-forming units per DC. 100 ng/ml Escherichia coli O111:B4 lipopolysaccharide (LPS) and L.
plantarum (Lp) were used as positive and negative control, respectively. After 48 h of stimulation, supernatants were collected and TNF (A), IL-12 (B),
IFNc (C), IL-6 (D) and IL-10 (E) cytokine production was measured by sandwich ELISA (Quantikine). *p,0.05,**p,0.001. Results are representative of
one of three independent experiments.
doi:10.1371/journal.pone.0011199.g007
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chemokine ligand 8 (IL-8) and activate other pro-inflammatory
pathways that in turn coordinate the innate immune response
[37]. The absence of IL-8 secretion by IECs in the presence of
recombinant L. plantarum is consistent with previous findings [38],
[39], [40] and suggests that an oral vaccine based in L. plantarum
expressing the OspA lipoprotein would not induce the local
adverse inflammatory effects attributed to pathogenic bacteria.
In the lamina propria of the intestine, the adaptive immune
response is oriented towards tolerance and it involves suppression
of Th1 cytokines such as IL-12 and activation of regulatory T cells
that inhibit the proliferation of other T cells through production of
IL-10 and TGFb1 [22], [23], [41], [37]. Together with IECs,
dendritic cells (DCs) interact with luminal bacteria [37] either
through receiving M-cell delivered bacterial cargo or through
extension of their own pseudopods across the IEC monolayer [42],
[43], [43]. When we stimulated human PBMC-derived-dendritic-
cells (PBMC/DCs) with recombinant L. plantarum expressing the
OspA lipoprotein, but not the unlipidated mutant, we observed
that pro-inflammatory cytokines TNFa, IFNc and IL-6 were
markedly upregulated. In addition, we observed an increase of
anti-inflammatory cytokine IL-10. When we stimulated monocyte
derived dendritic cells (MDDC) with L. plantarum expressing
lipidated OspA, but not unlipidated OspA, we observed that pro-
inflammatory cytokines TNFa and IL-12 were markedly upregu-
lated. Here too, we observed an increase of anti-inflammatory
cytokine IL-10. Differences in detection of cytokines in both assays
can be explained by the fact that in the former (PBMC/DC) assay
we expect to have a mixed population of monocyte derived
dendritic cells, T cells, B cells and NK cells, and in the later
(MDDC), we expect to have a relatively pure population of
dendritic cells. These data indicate that recombinant OspA-
Figure 8. Antibody response to oral administration of recombinant L. plantarum: serological IgG. C3H-HeJ mice were inoculated
intragastrically with L. plantarum expressing OspA (LpA) or the mutant OspAD17 (LpAD17). Control mice were inoculated with L. plantarum (Lp). Serum
samples were collected at days 0, 14, 28, 49 and 68, and specific serological anti-OspA total IgG (A), IgG1 (B) and IgG2a (C) antibodies were measured
by indirect ELISA. The results are expressed as Optical Density at 450 nm (OD450). The average of triplicate samples per mouse was determined and
the error bar indicates standard deviation. *p,0.05, **p,0.01. Results are representative of one of three independent experiments. n=4 mice per
group.
doi:10.1371/journal.pone.0011199.g008
Figure 9. Antibody response to oral administration of recombinant L. plantarum: mucosal IgA. C3H-HeJ mice were inoculated
intragastrically with L. plantarum expressing OspA (LpA) or the mutant OspAD17 (LpAD17). Control mice were inoculated with L. plantarum (Lp).
Specific mucosal anti-OspA IgA antibodies were measured by indirect ELISA in broncheoalveolar lavage (BAL) (A) and stool (B) collected on day 68.
The results corresponding to each mouse are expressed as Optical Density at 450 nm (OD450) of the mean endpoint titer. Results are representative of
one of three independent experiments. n=4 mice per group. ns, not significant.
doi:10.1371/journal.pone.0011199.g009
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Th2 cell mediated immunity and that, lipidation of the antigen in
the delivery agent plays an active role in this response.
The lipid attachment in OspA seems to be a critical determinant
of the mature protein immunogenicity [35]. Furthermore, the
OspA leader peptide has been fused to different proteins to
generate potent lipo-antigens that induce strong B (IgG) and T-cell
(helper CD4
+ and cytotoxic CD8+) responses [44], [45]. Because
lipoproteins and OspA are known to trigger TLR2-based
receptors [46], [47], we stimulated monocyte derived dendritic
cells with purified proteins in order to access the effect of the naked
protein on cytokine induction. We observed that wildtype OspA
(wtOspA) induced TNFa and IL-10 but it did not induce IL-12 or
IFNc. In the absence of the leader peptide, as in mutOspA, the
TNFa response was abrogated and IL-10 was reduced in half. In
contrast, if OspA is delivered in Lactobacillus we also observe an
effect on the production of IL-12. This effect appears to be related
to the delivery vehicle in which OspA is presented. Furthermore,
our results show that mutation of the Cys
17 on the leader peptide
of OspA decreases significantly the production of pro- and anti-
inflammatory cytokines, and that this effect is related to the
lipidation of OspA. In addition, we observed that lipidation of
protein is not essential to induce a specific humoral immune
response to OspA (systemic IgG and mucosal IgA) when the
antigen is orally delivered by Lactobacillus. The adjuvant effect of
Lactobacillus as oral carrier, exerts a synergized effect along with the
intrinsic antigenicity of unlipidated OspA. This result differs with
others, where the lipid modification of OspA seems to be essential
to induce a humoral immune response, when the soluble
unlipidated antigen is delivered subcutaneously without a cellular
carrier [35]. In addition, we have found that the mutation of OspA
Cys
17 skewed the systemic IgG production towards IgG2a,
probably as result of a shift from a Th2 to a Th1 response. Over
all, our data suggest that the lipidation of OspA has a clear role on
the mixed Th1/Th2 cellular and humoral immune response to
orally administered Lactobacillus expressing OspA.
Given that we inoculate our animals with very high doses of
vaccine for long periods of time our results appear to contradict
the dogma that high and repeated doses of stimulating antigen
induces oral tolerance [48]. This might be due to the fact that our
antigen is delivered via a bacterial system rather than purified
protein and therefore the amount that is actually exposed to the
mucosal immune system might be much less than the naked
antigen.
In summary, we investigated the mechanism by which a
mucosal vaccine based in recombinant LAB breaks the immuno-
logical tolerance of the gut in order to elicit a protective immune
response. It is possible that mucosal tolerance may have been
broken by two different mechanisms. In the first scenario, M
cells might transport whole recombinant L. plantarum or OspA
lipoprotein as it is released from lysed recombinant L. plantarum
across the epithelium where they can induce primary immune
responses [1]. In a second scenario, as dendritic cells uptake
recombinant LAB and recognized it as the pathogen, the bacteria
are no longer retained at the mesenteric lymphnode, as it happens
when DCs are loaded with commensal bacteria, but instead
migrate to secondary lymphoid tissue and present antigen to
T-cells in a systemic environment that is not tolerigenic [49].
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